2Ambrose JA, Tannenbuum MA, Alexopoulos D, et al. Angiographie progression of coronary artery disease and the development of myocardial infarction[ J]. J Am Coll Cardiol, 1988,12( 1 ) : 56-62.
3Libby P. Current concepts of the pathogensis of the acute coronary syndromes[J]. Circulation ,2001,104(3) :365-372.
4Ross R. Atherosclerosis is an inflammatory disease [ J ]. New Engl J Med, 1999,340(2) :115-126.
5Pasterkamp G, Schoneveld AH, van der Wal AC, et al. Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries[ J ]. Artefioscler Thromb Vasc Biol, 1999,19 ( 1 ) : 54-58.
6Rifai N, Ridker PM. Inflammatory markers and coronary heart disease[J]. Curt Opin Lipidol,2002,13(4) :383-389.
7Williams JK, Sukhova GK, Herrington DM, et al. Pravastatin has cholesterol- lowering independent effects on the artery wall of atherosclerotic monkey[J] .J Am Coll Cardiol, 1998,31(3):684-691.
9Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors(statin) increase endothelial progenitor cells via the PI3-kinase/Akt pathway[ J ]. J Clin Invest, 2001,108 ( 3 ) : 391-397.
10Strandberg TE,Vanhanen H,Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary heart disease[J]. Lancet, 1999,353(9147) :118-119.
4Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells[J]. Atherosclerosis, 1999, 147(2): 253-261.
5Rackley CE. New clinical markers predictive of cardiovascular disease: the role of inflammatory mediators[J]. Cardiol Rev, 2004, 12: 151-157.
6Murakami H, Tamasawa N, Matsui J, et al. Plasma levels of soluble vascular adhesion molecular-1 and cholesterol oxidation product in type 2 diabetic patients with nephropathy[J]. J Atheroscler Thromb, 2001, 8( 1 ): 21-24.
7Guan JZ, Murakami H, Yamato K, et al. Effects of fluvastatin in type 2 diabetic patients with hyperlipidemia: reduction in cholesterol oxidation products and VCAM-1 [J]. J Atheroscler Thromb, 2004, 11(2): 56-61.
8Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial[J]. Lancet, 2002, 360: 7-22.
9Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability[J]. Cardiovasc Res, 2000, 47: 648-657.
10Hernandez TL, Capell WH, Wolfe P, et al. Time course of C-reactive protein with simvastatin therapy in patients with type 2 diabetes mellitus[J]. Am J Cardiol, 2006, 98(12): 1656-1659.
